XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor

BACKGROUND: High-risk neuroblastoma patients have a 5-year survival rate of less than 50%. It’s an urgent need to identify new therapeutic targets and the appropriate drugs. Exportin-1 (XPO1), also known as chromosomal region maintenance 1, plays important roles in the progression of tumorigenesis....

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Lijia, Cheng, Cheng, Duan, Peiwen, Chen, Kai, Wu, Yeming, Wu, Zhixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359549/
https://www.ncbi.nlm.nih.gov/pubmed/34384466
http://dx.doi.org/10.1186/s13046-021-02044-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359549/
https://www.ncbi.nlm.nih.gov/pubmed/34384466
http://dx.doi.org/10.1186/s13046-021-02044-z

Ejemplares similares